Exact Sciences announced today that it acquired Resolution Bioscience from Agilent Technologies.

According to a release, Resolution Bioscience’s blood-based diagnostic tests complement Exact Sciences’ Precision Oncology portfolio, providing a more complete cancer treatment solution for patients, healthcare professionals and biopharma partners.

“We are excited to work with the Resolution Bioscience team to integrate their innovative diagnostics into our Precision Oncology portfolio,” Exact Sciences General Manager of Precision Oncology Brian Baranick said in a statement. “Resolution Bioscience’s high-quality liquid therapy selection platform perfectly complements our OncoExTra test, allowing Exact Sciences to help more cancer patients determine their best treatment options.”

Financial terms of the agreement were not disclosed.